0 254

Cited 0 times in

Clinical impact of recombinant human erythropoietin in the treatment of anemia of gynecologic malignancies

Other Titles
 항암화학요법을 시행받은 부인암 환자에서 recombinant human erythropoietin의 임상적 유용성 
 김희연 ; 김영태 ; 김재욱 ; 김성훈 ; 김재훈 ; 박용원 
 Korean Journal of Obstetrics and Gynecology (대한산부인과학회잡지), Vol.48(1) : 80-87, 2005 
Journal Title
 Korean Journal of Obstetrics and Gynecology  (대한산부인과학회잡지) 
Issue Date
Objective: To examine the influence of erythropoietin (Epokaine prefil。) on transfusion requirements, serum hemoglobin levels in patients with gynecologic malignancies under polychemotherapy and chemotherapy associated anemia. Methods: From January 2001 to March 2003, 70 patients treated with chemotherapy due to gynecologic cancer from Severance hospital were included into this study. Patients were assigned to one of two groups (case group (n=28) and control group (n=42)). Patients in case group received 2000 U or 6000 U Epokaine。subcutaneously two or three times a week for more than 3 cycles (9 weeks), and patients in control group didn’t received Epokaine。 (n=42). If the hemoglobin levels of 1st, 2nd and 3rd cycle >1 g/dL above the baseline value and/or >12 g/dL, patients were classified as responders. Patients who required blood transfusions or if the hemoglobin levels of 1st, 2nd and 3rd cycle <1 g/dL were as non-responders. Results: 28 cases of 70 patients were assessable for response and complication to Epokaine。 application. In the Epokaine。 group, 53%, 64%, 71% of the patients responded to the treatment (at 1st, 2nd and 3rd cycle, respectively) and only 7 patients (21.4%) required blood transfusions, whereas 28 patients in control group (66.7%) needed transfusion. Mean transfused units were 1.56 in case group and 3.55 in the control group (P=0.03). In case group, mean hemoglobin levels were significantly increased after the 1st, 2nd and 3rd cycle of chemotherapy (0.73 g/dL, 1.34 g/dL, 1.65 g/dL, respectively) compared with the mean baseline value. Conclusion: We concluded that Epokaine。 significantly decreases transfusions requirements and increases serum hemoglobin levels in patients with gynecological malignancies who are undergoing polychemotherapy. Therefore, Epokaine。 would be effective in the treatment of anemia of gynecologic cancer patients receiving polychemotherapy.
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Obstetrics & Gynecology
Yonsei Authors
사서에게 알리기
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.